A
Aclarion, Inc.
Period
FY 2025
Revenue
$75.7K
Net Income
$-7.23M
Total Assets
$13.67M
Equity
$12.84M
Shares Out
2.46M
Op. Cash Flow
$-7.16M
Business
Aclarion is a healthcare technology company that develops diagnostic software using Magnetic Resonance Spectroscopy and proprietary biomarkers to identify painful intervertebral discs in patients with discogenic low back pain. The company's primary product, NOCISCAN, comprises two cloud-based software modules (NOCICALC and NOCIGRAM) that post-process MRS exam data to generate diagnostic reports assisting surgeons in treatment planning. Aclarion serves the U.S. spine fusion market through clinical registries and machine learning, supported by an exclusive license to UCSF biomarker technology.
Summary from 10-K filed 2026-03-18
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 75,730 | 45,724 | 75,404 | 60,444 | 60,292 | |
| Cost of revenue | 68,902 | 84,658 | 75,728 | 65,298 | 69,175 | |
| Gross profit (loss) | 6,828 | −38,934 | −324 | −4,854 | −8,883 | |
| Sales and marketing | 2 | 976,554 | 757,004 | 498,003 | 330,814 | |
| Research and development | 1 | 888,766 | 873,336 | 1 | 787,850 | |
| General and administrative | 4 | 4 | 3 | 4 | 2 | |
| Total operating expenses | 7 | 5 | 5 | 6 | 3 | |
| Loss from operations | −7 | −6 | −5 | −6 | −3 | |
| Interest expense | 0 | −535,470 | −608,288 | — | — | |
| Loss on exchange of debt | 0 | −1 | 0 | — | — | |
| Gain on extinguishment of debt | 73,272 | 6,058 | — | — | — | |
| Changes in fair value of warrant and derivative liabilities | 11,806 | 335,033 | 646,319 | 0 | — | |
| Penalties and settlements | −672,625 | −212,453 | 0 | — | — | |
| Interest income | 411,061 | 318 | — | — | — | |
| Other, net | −4,752 | −49 | −562 | 521 | 4,458 | |
| Total other expense | −181,238 | −1 | −35,393 | −2 | −2 | |
| Loss before income taxes | −7 | −7 | −5 | −7 | — | |
| Income tax provision | 0 | 0 | 0 | 0 | 0 | |
| Net loss | −7 | −7 | −5 | −7 | −5 | |
| Dividends on preferred stock | −6,683 | −59,675 | 0 | −415,523 | −1 | |
| Net loss allocable to common stockholders | −7 | −7 | −5 | −7 | −6 | |
| Net loss per share allocable to common stockholders, basic | −13.61 | −7,479 | −79,782 | −19.61 | −6.58 | |
| Net loss per share allocable to common stockholders, diluted | −13.61 | −7,479 | −79,782 | −19.61 | −6.58 | |
| Weighted average shares of common stock outstanding, basic | 532,036 | 943 | 62 | 381,598 | 905,685 | |
| Weighted average shares of common stock outstanding, diluted | 532,036 | 943 | 62 | 381,598 | 905,685 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 12 | 453,661 | 1 | 1 | 432,530 | |
| Restricted cash | 25,000 | 10,000 | 10,000 | 10,000 | 20,000 | |
| Accounts receivable, net | 29,680 | 18,326 | 13,270 | 18,569 | 6,280 | |
| Prepaid expense | 316,235 | 0 | 245,030 | 199,701 | 273,394 | |
| Other current assets | 10,000 | 39,002 | — | — | — | |
| Total current assets | 12 | 824,279 | 1 | 2 | 732,204 | |
| Property and equipment, net | 24,169 | 5,499 | 1,782 | 3,346 | 12,636 | |
| Intangible assets, net | 1 | 1 | 1 | 1 | 1 | |
| Total non-current assets | 1 | 1 | 1 | 1 | 1 | |
| Total assets | 14 | 2 | 2 | 3 | 2 | |
| Accounts payable | 324,470 | 531,603 | 760,535 | 462,202 | 1 | |
| Accrued and other liabilities | 504,262 | 404,228 | 857,722 | 226,469 | 696,582 | |
| Warrant liability | 63 | 11,869 | 121,326 | 0 | — | |
| Liability to issue equity | 0 | 80,772 | 33,297 | 0 | 0 | |
| Total current liabilities | 837,287 | 1 | 3 | 688,671 | 8 | |
| Total liabilities | 837,287 | 1 | — | — | — | |
| Commitments and contingencies (see Note 11) | — | — | — | — | — | |
| Additional paid-in capital | 71 | 52 | 44 | 42 | 19 | |
| Accumulated deficit | −58 | −51 | −44 | −39 | −32 | |
| Total stockholders equity | 13 | 970,057 | −727,995 | 2 | −13 | |
| Total liabilities and stockholders equity | 14 | 2 | 2 | 3 | 2 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 227,406 | 193,139 | 162,670 | — | — | |
| Share-based compensation | 105,368 | 287,455 | 456,001 | 1 | 177,489 | |
| Amendment of warrants | 48,087 | 0 | — | — | — | |
| Non-cash settlements | 58,272 | 0 | — | — | — | |
| Loss on extinguishment of debt | 0 | 111,928 | 0 | — | — | |
| Amortization of deferred issuance costs | 0 | 471,387 | 497,656 | 0 | — | |
| Change in fair value related to warrants and derivative | −11,806 | −335,033 | −646,319 | 0 | — | |
| Non-cash interest related to bridge funding | 0 | 58,002 | 98,685 | 0 | — | |
| Non-cash expenses related to equity line agreement | 0 | 425,367 | 0 | — | — | |
| Accounts receivable | −11,354 | 7,271 | −1,491 | −12,290 | 16,222 | |
| Prepaids and other current assets | 16,057 | −287,663 | −38,539 | −87,522 | −210,765 | |
| Accounts payable | −198,641 | −156,403 | 220,633 | −603,102 | 199,604 | |
| Accrued and other liabilities | −163,964 | −127,449 | 448,459 | −113,893 | 509,806 | |
| Net cash used in operating activities | −7 | −5 | −4 | −5 | −2 | |
| Intangible assets Patents | −182,374 | −316,822 | −119,522 | −208,870 | −102,005 | |
| Fixed assets | −21,528 | −5,115 | 0 | — | — | |
| Net cash used in investing activities | −203,902 | −321,937 | −119,522 | −207,870 | −102,005 | |
| Public offering of common stock and warrants | 15 | 3 | — | — | — | |
| Registered direct offerings of common stock | 6 | 0 | 0 | 9 | — | |
| Proceeds from direct offering of prefunded warrants | 2 | 0 | — | — | — | |
| Proceeds from sale of preferred stock | 0 | 1 | 1,000 | 0 | — | |
| Proceeds from sale of common stock and warrants, ATM | 0 | 288,294 | — | — | — | |
| Common stock cash issuance costs | −2 | −788,099 | 0 | −365,060 | — | |
| Exercise of Series C warrants | 336,441 | 0 | — | — | — | |
| Redemption of Series B Preferred stock | −1 | 0 | — | — | — | |
| Proceeds from common stock and warrant RegA+ offering | 0 | 529,254 | — | — | — | |
| Proceeds from equity line | 0 | 2 | 1 | 0 | — | |
| Repayment of promissory notes | 0 | −300,973 | 0 | −2 | 0 | |
| Equity line cash issuance costs | 0 | −367,865 | −74,916 | — | — | |
| Preferred stock cash issuance costs | 0 | −90,000 | 0 | — | — | |
| Net cash provided by financing activities | 19 | 5 | 3 | 6 | 3 | |
| Net increase (decrease) in cash and cash equivalents | 12 | −567,408 | −451,737 | 1 | 437,546 | |
| Cash paid for interest | 0 | 13,072 | 10,705 | — | — | |
| Cash paid for income taxes | 1,691 | 0 | 0 | — | — | |
| Capitalization of Series B preferred stock dividends | 5,425 | 0 | — | — | — | |
| Capitalization of Series C preferred stock dividends | 1,258 | 0 | — | — | — | |
| Conversion of Series C preferred stock to common stock | 548,534 | 0 | — | — | — | |
| Cashless exercise of B warrants to common stock | 10 | 0 | — | — | — | |
| Dividends accrued on preferred shares | 0 | 59,675 | 0 | 415,523 | 1 | |
| Exchange of indebtedness for common shares | 0 | 2 | 0 | — | — | |
| Exchange of indebtedness for preferred shares | 0 | 930,052 | 0 | — | — | |
| Conversion of preferred stock to common stock | 0 | 129,999 | 0 | 26 | 0 | |
| Issuance of common shares related to restricted stock units | 0 | 216,597 | 0 | — | — | |
| Issuance of commitment shares related to bridge funding | 0 | 33,297 | 175,619 | 0 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Aclarion, Inc.'s CIK number?
Aclarion, Inc.'s SEC CIK number is 0001635077 (1635077). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Aclarion, Inc.'s SEC filings?
All of Aclarion, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.